A specialized, doctor-led med-tech consultancy that develops medical device and pharmaceutical companies and factories end-to-end across the GCC and Egypt. We don't hand over strategies — we carry a venture from feasibility to a running business, and we stand accountable for the outcome.
Most of the risk in medical manufacturing sits in the execution, not the strategy. The gap between a strategy document and a functioning, compliant, commercially operational facility is where ventures stall — and it is exactly the gap Bayeux was built to close. Not an advisor, not a coordinator: a firm that executes the full build.
The firm is led by medical professionals — doctors and clinical specialists who have operated in the manufacturing environment at factory level, not studied it from the outside. Clinical judgment sits at the centre of every decision, from clean-room design to surgeon engagement, which is why the advice holds up in practice rather than only on paper.
Two capabilities set Bayeux apart: a vetted network of 60–80 international suppliers across Europe, the US and Asia — built through real projects, not assembled for an engagement — and full in-house delivery, with feasibility, financial modeling, training, device development and process design all executed within the firm. Nothing critical is outsourced; standards are controlled and timelines are owned.
The GCC and Egypt are at a structural inflection point. Vision 2030 in Saudi Arabia, the UAE's industrial diversification agenda, and Egypt's national manufacturing programs have made local medical manufacturing a mandate — not a preference. The demand for partners who can actually execute that ambition is growing faster than the supply, and Bayeux intends to be the name investors, governments and manufacturers turn to when the goal is not to study the opportunity but to build it.
Every engagement is measured against one non-negotiable standard: did the venture get built, approved, and brought to market? Not whether the strategy was well received or the report comprehensive — whether the factory is running, the product is registered, the team is in place, and the revenue is being generated. That standard is the filter through which Bayeux makes every decision.
Not claims of superior service within a conventional model — structural differences built through years of operating in the medical manufacturing environment, at the level where decisions are made and their consequences are felt.
Led by doctors and clinical specialists who have operated at the clinical, regulatory and manufacturing level simultaneously. In a sector where products go into patients, clinical leadership is not a differentiator — it is a prerequisite for doing the work correctly.
Credibility built by doing the work — building production lines, qualifying equipment, managing GMP audits, writing SOPs, and solving the contamination problems and regulatory findings that only surface when a factory is actually running. Advice that holds up under operational pressure.
Not a list of contacts, but relationships forged through real project execution — equipment, raw materials, components, technology and OBL/OEM partners across Europe, the US and Asia. The operational foundation for fulfilling virtually any requirement, from a single component to a full production line.
The full Gulf regulatory landscape — Bahrain, Kuwait, Oman, Qatar, the UAE — managed as one multi-market strategy so a single portfolio reaches all of them, with the practical knowledge of how ISO 13485, CE Mark, EU MDR and EFDA interact with SFDA. We manage the process; we don't describe it.
Most projects run through a chain of separate engagements — each handoff a point of failure where accountability gaps open. Bayeux eliminates the chain: one engagement, one team, one accountable partner from feasibility to launch. The client carries one relationship; Bayeux carries the outcome.
Depth in the highest-complexity product category — precision tolerances, quality systems that prove dimensional accuracy for every implant, surgeon-relationship-driven adoption, and the most demanding regulatory pathways. The area where Bayeux's advantage is most concentrated and hardest to replicate.
Bayeux's principal market and operational centre — the largest, most strategically significant med-tech investment environment in the Middle East, driven by Vision 2030's localization mandate. Deep SFDA expertise and on-the-ground relationships across hospitals, procurement and government make it where our advantage is most concentrated.
The GCC's fastest-evolving med-tech market — maturing regulation, active localization across Abu Dhabi and Dubai, strong investor appetite, and free-zone infrastructure. Our Dubai branch is also Bayeux's primary interface with the international investor base entering the region.
Bayeux's home market and longest-established presence — a large skilled workforce, competitive production economics, and a strategic base serving both the GCC and North Africa, with deep relationships across the Egyptian healthcare system and EDA regulatory expertise.
Regulatory alignment and market access across Bahrain, Kuwait, Oman and Qatar — so a product registered in Saudi Arabia can reach the entire Gulf without rebuilding the regulatory and commercial infrastructure in each jurisdiction.
West Africa's largest healthcare market and the natural anchor for pan-African manufacturing and distribution — the same capability model deployed in the GCC and Egypt, adapted to the Nigerian regulatory environment.
A bridge between our regional operations and Europe's manufacturing, technology and regulatory ecosystems — EU MDR-aligned, with an advanced manufacturing sector that strengthens sourcing and technology transfer across the network.
We don't leave when the building is complete. We leave when the business is running.Bayeux — Full cycle. Full commitment.
Doctor-led, end-to-end development of medical device and pharmaceutical ventures across the GCC and Egypt. We don't just advise — we build.